Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
With breast cancer so often in the news, it is easy to forget
that the diagnosis is an emotional and life-changing event for
an individual patient. In the United States (US), an estimated
231,840 women and 2,350 men1 were diagnosed with invasive
breast cancer in 2015. One in every 8 women in the US will be
diagnosed with breast cancer during her lifetime. In contrast,
a man’s lifetime risk is about 1 in 1000. Following skin cancer,
breast cancer is the most commonly diagnosed cancer among
women. During recent years, the incidence of breast cancer has
been stable for Caucasian women; however, it has increased
slightly for African-American women, due in part to longer
life expectancy and improved screening and detection. Because
of earlier detection and improved treatment, the death rate for
breast cancer in the US has declined since 19891; however, it is
still the second leading cause of cancer death in women, after
lung cancer. In 2015, an estimated 40,290 women will die from
Over the past decade, the treatment options for breast cancer
have expanded, especially for advanced disease. One area of
progress that has made an impact in the community setting is
the development of new oral medications for advanced disease.
This issue provides an overview of breast cancer in women,
with a focus on the use of newer,
oral agents for the treatment of
advanced disease. Along with surgery, radiation, chemotherapy,
and hormonal (anti-estrogen) therapy, the use of targeted agents
has become routine in the fight against breast cancer.
providers, including pharmacists, have an obligation to be
well informed about these agents – especially the oral drugs – in
order to adequately support patients in the community setting.
Publication Date: 12/20/2015
Expiration Date: 12/20/2018
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc.
The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and
is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased,
balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic
area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure
that every program presents information that is current, accurate, relevant to "real world" health care
providers, and written in an easy reading, "plain English" style.
Ashton Hullett, PharmD, Clinical Pharmacist (Oncology), NorthShore University HealthSystem Kellogg Cancer Center;
Cheryl Jee, PharmD, BCOP, Oncology Pharmacist, NorthShore University HealthSystem Kellogg Outpatient Pharmacy; and
Kathryn Schiavo, PharmD, Pharmacy Manager for the NorthShore University HealthSystem Kellogg Outpatient Pharmacy in Illinois.
Dr. Ashton Hullett, Dr. Cheryl Jee, and Dr.Kathryn Schiavo report no financial or personal relationship with any
commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.
This accredited program is targeted to pharmacists and nurses.
Goals & Objectives
At the conclusion of this program, participants will be able to:
- Review the risk factors and screening for breast cancer. Discuss the importance of hormone receptor and HER2 status.
- Describe the roles of chemotherapy, targeted therapy, and hormonal therapy in breast cancer treatment. Describe
treatment for risk reduction.
- List 4 classes of hormonal agents and discuss their adverse effects. Name the drug(s) in each class and state their
indications and recommended doses.
- Identify the indications, doses, adverse effects, and precautions for the 3 oral targeted drugs and 1 oral chemotherapy
agent. Counsel patients about taking them properly.
The Rx Consultant is a publication of Continuing Education Network, Inc.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a
provider of continuing pharmacy education.
Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.
ACPE Universal Activity Number: 0428-0000-15-013-H01-P
Exam & Credit Statement Procedures
Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and
Editorial and Review Board
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA
Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA
Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA
Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System
Adjunct Clinical Professor
College of Pharmacy
Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Visiting Associate Professor and Lecturer
Samuel Merritt University
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
About the Rx Consultant
The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to
educate patients about drugs and manage drug therapy. The reader is responsible for confirming
the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)